Direkt zum Inhalt
Merck

P-055

Supelco

Propranolol -hydrochlorid

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C16H21NO2·HCl
CAS-Nummer:
Molekulargewicht:
295.80
EG-Nummer:
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

certified reference material

Qualitätsniveau

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

1.0 mg/mL in methanol (as free base)

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

clinical testing

Format

single component solution

Lagertemp.

−20°C

SMILES String

Cl.CC(C)NCC(O)COc1cccc2ccccc12

InChI

1S/C16H21NO2.ClH/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;/h3-9,12,14,17-18H,10-11H2,1-2H3;1H

InChIKey

ZMRUPTIKESYGQW-UHFFFAOYSA-N

Angaben zum Gen

Allgemeine Beschreibung

A certified reference solution suitable for use as starting material in calibrators and controls for LC/MS or GC/MS testing methods in clinical and diagnostic testing, urine drug testing, forensic analysis, or clinical toxicology. Propranolol is a sympatholytic non-selective beta blocker used to treat a variety of medical conditions including hypertension, anxiety and panic. The drug is sold under numerous brand names such as Inderal®, Avlocardyl, Deralin, and Dociton.

Anwendung

<ul>
<li><strong>Propranolol hydrochloride solution for infantile hemangioma:</strong>Liposomal formulations of propranolol hydrochloride have been developed for the treatment of infantile hemangioma, offering a targeted therapeutic approach in pediatric dermatology (Nifli et al., 2024).</li>
<li><strong>Propranolol hydrochloride:</strong> Research on the percutaneous absorption of solvent-deposited propranolol hydrochloride across different skin layers provides insights into its properties like it can be used as a function of dose and ionization state and as a calibration standard (Tonnis et al., 2024).</li>
</ul>

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Inderal is a registered trademark of Cranford Pharmaceuticals, LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 1

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Bojko Bjelakovic et al.
Drug design, development and therapy, 7, 127-129 (2013-03-08)
We hypothesized that some characteristics of beta-blockers, including negative inotropic, peripheral vasoconstrictor, and antiangiogenic effects, might be potentially useful in treating children with epistaxis. From June 2010 to March 2012, a total of seven children with recurrent primary epistaxis resistant
Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study.
Imad R Makhoul et al.
Archives of disease in childhood, 98(7), 565-567 (2013-05-02)
[Propranolol first choice in infantile hemangiomas. Large randomized trials are needed to determine the dosage and duration of treatment].
Carl-Fredrik Wahlgren
Lakartidningen, 110(19-20), 938-939 (2013-06-12)
Retrospective review of adverse effects from propranolol in infants.
Eun-Kyung M Kwon et al.
JAMA dermatology, 149(4), 484-485 (2013-05-30)
Philip M Short et al.
American journal of respiratory and critical care medicine, 187(12), 1308-1314 (2013-04-19)
Unblinded studies have shown improvements in airway hyperresponsiveness with chronic nadolol in steroid-naive patients with asthma. To assess the effects of chronic nonselective β-blockade as add-on to inhaled corticosteroids (ICS) in patients with asthma. A double-blind randomized placebo-controlled crossover trial

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.